1333 related articles for article (PubMed ID: 34531868)
1. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
2. Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.
Ye B; Shi J; Kang H; Oyebamiji O; Hill D; Yu H; Ness S; Ye F; Ping J; He J; Edwards J; Zhao YY; Guo Y
RNA Biol; 2020 Nov; 17(11):1666-1673. PubMed ID: 31607216
[TBL] [Abstract][Full Text] [Related]
3. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
[TBL] [Abstract][Full Text] [Related]
4. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
Front Immunol; 2022; 13():903461. PubMed ID: 35663977
[TBL] [Abstract][Full Text] [Related]
5. Differential Expression of the
Hu J; Xu J; Feng X; Li Y; Hua F; Xu G
Front Cell Dev Biol; 2021; 9():700661. PubMed ID: 34631699
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
7. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
8. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
[TBL] [Abstract][Full Text] [Related]
9. Role of CD47 in tumor immunity: a potential target for combination therapy.
Huang J; Liu F; Li C; Liang X; Li C; Liu Y; Yi Z; Zhang L; Fu S; Zeng Y
Sci Rep; 2022 Jun; 12(1):9803. PubMed ID: 35697717
[TBL] [Abstract][Full Text] [Related]
10. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract][Full Text] [Related]
12. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis of oncogenic role of Programmed Cell Death 2 Like (PDCD2L) and validation in colorectal cancer.
Gao H; Xu C; Liang J; Ge S; Zhang F; Tuo Y; Shi H; Han A
Cancer Cell Int; 2022 Feb; 22(1):100. PubMed ID: 35216602
[TBL] [Abstract][Full Text] [Related]
15. [A pan-cancer analysis of TTC9A expression level and its correlation with prognosis and immune microenvironment].
Yao Y; Liu J; Zhou X; Liu Z; Qiu S; He Y; Zhou X
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Jan; 44(1):70-82. PubMed ID: 38293978
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance.
Ma J; Jin Y; Gong B; Li L; Zhao Q
Discov Oncol; 2022 Mar; 13(1):17. PubMed ID: 35312867
[TBL] [Abstract][Full Text] [Related]
17. ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.
Deng T; Liu Y; Zhuang J; Tang Y; Huo Q
Front Oncol; 2022; 12():632042. PubMed ID: 35515103
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of the lncRNA BACE1-AS as Immune-Related Influencing Factor in Tumorigenesis following Pan-Carcinoma Analysis.
Wang M; Chen D; Xu Y; Qiu M; Jiang X; Xiong Z
J Immunol Res; 2021; 2021():1589864. PubMed ID: 34926701
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis reveals methylenetetrahydrofolate dehydrogenase 1-like as an independent shared diagnostic and prognostic biomarker in five different human cancers.
Sial N; Rehman JU; Saeed S; Ahmad M; Hameed Y; Atif M; Rehman A; Asif R; Ahmed H; Hussain MS; Khan MR; Ambreen A; Ambreen A
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908119
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
Song J; Yang R; Wei R; Du Y; He P; Liu X
Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
